<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292746</url>
  </required_header>
  <id_info>
    <org_study_id>EC_FA001</org_study_id>
    <nct_id>NCT01292746</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Low Level Laser Light on Hair Growth on the Female Human Scalp</brief_title>
  <official_title>An Evaluation of the Effect of the Erchonia ML Scanner (MLS) on the Treatment of Androgenic Alopecia in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine if the Erchonia® ML Scanner (MLS) low
      level laser light device can help to regrow hair on the scalp of females experiencing hair
      loss or thinning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 20 million women in the United States suffer from hair loss, and about 40% of those
      women are under forty years of age. The emotional aspects of hair loss for females include
      anxiety and depression, frustration and poor self-esteem. Androgenetic alopecia is a common
      cause of female balding and the most likely reason for excessive hair loss.

      It is believed that light therapy of the scalp will provide an effective means to reduce hair
      loss and/or stimulate hair growth in females with androgenetic alopecia. Results of previous
      studies on low level laser therapy (LLLT) have demonstrated a variety of in vitro and in vivo
      effects including increased blood flow, accelerated wound healing, enhanced production of
      cytokines and other cellular mediators, increased cellular proliferation, among a panoply of
      other effects. Enhanced hair growth has been observed adjacent to treated areas in various
      animal models investigating the effects of LLLT. Uncontrolled studies in humans and spa-based
      therapies in Europe appear to show that the periodic application of low intensity light
      therapy reduces hair loss and appears to increase hair growth. The majority of these
      applications utilize light in the red and near-infrared portions of the spectrum.

      The Erchonia MLS low level laser is being evaluated for its potential to improve the quality
      and quantity of hair on the female scalp. This may improve the quality of life as a result of
      improved self-image and may potentially delay or reduce the need for surgical procedures such
      as hair transplantation. A successful local therapy would mitigate or reduce the need for
      systemic agents such as minoxidil and finasteride, thereby minimizing the potential side
      effects of these therapies.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment and subject study compliance was difficult
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area</measure>
    <time_frame>Baseline and 13 Weeks</time_frame>
    <description>Non-vellus terminal hair count was calculated across a tattooed 3 cm diameter scalp area from digital photographs of the area by independent blinded evaluator employing macroimage analysis software.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Female Pattern Alopecia</condition>
  <arm_group>
    <arm_group_label>Erchonia ML Scanner (MLS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erchonia MLS</intervention_name>
    <description>The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
    <arm_group_label>Erchonia ML Scanner (MLS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female pattern androgenic alopecia defined as:

               -  discernable decrease in hair density on the top of the scalp relative to the
                  sides and back of the scalp (ii) classifications I-3, I-4, II-1, II-2 according
                  to the Ludwig and Savin Hair Loss Scale

          -  Notable hair loss/thinning onset within the past five years.

          -  Progressive/active hair loss/thinning within the last 12 months.

          -  Skin type I through IV according to the Fitzpatrick Skin Type Scale.

          -  Healthy, balanced scalp, determined as one that shows no indication of notable:
             dryness, flaking, dandruff (pityriasis), redness, irritation, inflammation, itching,
             greasy/oily texture, odor, lesions, scalp acne or other significant dermatological
             conditions.

          -  PI or P2 on the American Society of Anesthesiologists (ASA) Physical Status
             Classification System.

          -  Willing and able to maintain same hair style, length, color and hair care regimen
             throughout study participation.

        Exclusion Criteria:

          -  Hair loss attributable to one or more of the following conditions: tinea capsitis,
             secondary syphilis, discoid lupus erythematosus: Inflammation, alopecia areata,
             trichotillomania, telogen effluvium, anagen effluvium, traumatic alopecia.

          -  Use of any of the following medications presently or during the prior 6 months:
             minoxidil, finasteride (or any other 5ᾳ-reductase inhibitor medications),medication
             with anti-androgenic properties (e.g. cyproterone, spironolactone, ketoconazole,
             flutamide and bicalutamide),topical estrogens, progesterone, tamoxifen, anabolic
             steroids, medications that can potentially cause hypertrichosis (e.g. ciclosporin,
             diazoxide, phenytoin and psoralens), oral glucocorticoids (inhaled glucocorticoids
             permitted), lithium, phenothiazines.

          -  Current use of other prescription and/or over-the-counter products known to affect
             hair growth and distribution (e.g. saw palmetto, fish oil, corticosteroids,
             antineoplastic agents, beta blockers, diazoxide, heparin, verapamil, warfarin, etc.).

          -  Medical, physical, or other contraindications for, or sensitivity to, light therapy
             (e.g. porphyria, photosensitizing drug therapies).

          -  Taking Hormonal Replacement Therapy.

          -  Conditions that may worsen with light therapy.

          -  History of poor wound healing.

          -  History of keloid formation.

          -  Prior hair restoration/transplantation surgery.

          -  Prior scalp reduction procedure(s).

          -  Other surgery to the scalp region (e.g. to remove a skin cancer lesion).

          -  Active skin infection, wound, or other external trauma to the scalp evaluation area.

          -  Active malignancy or any malignancy in the past five years in the scalp evaluation
             area.

          -  Dermatological condition (dermatitis, eczema, psoriasis, etc.) of the scalp other than
             female pattern hair loss.

          -  Significant scarring (e.g. from burns) in the scalp evaluation area.

          -  History of thyroid condition that may influence hair growth and loss.

          -  Underlying medical condition(s) known to adversely affect hair growth or hair pattern,
             such as HIV, connective tissue disease, inflammatory bowel disease.

          -  Current hair weaves.

          -  Use of non-breathable wigs.

          -  Hairstyle is a &quot;buzz&quot; cut, defined as hair cut to less than one inch in length.

          -  Tattooing of the scalp target evaluation area.

          -  Subject is pregnant, nursing, planning a pregnancy, or less than six months
             postpartum.

          -  Serious mental health illness such as dementia or schizophrenia; psychiatric
             hospitalization in the past two years.

          -  Developmental disability or cognitive impairment that would preclude adequate
             comprehension of the informed consent form and/or ability to record study
             measurements.

          -  Involvement in litigation/receiving disability benefits related in any way to the
             parameters of the study.

          -  Participation in research in the past 30 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M Thaxton, MD, FACOG</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Gynecology Specialists of Georgia</name>
      <address>
        <city>Evans</city>
        <state>Georgia</state>
        <zip>30809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>July 9, 2015</results_first_submitted>
  <results_first_submitted_qc>November 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2015</results_first_posted>
  <last_update_submitted>November 7, 2015</last_update_submitted>
  <last_update_submitted_qc>November 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erchonia MLS</title>
          <description>Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erchonia MLS</title>
          <description>The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-Vellus Terminal Hair Count</title>
          <description>Non-vellus terminal hair count per centimeter squared (cm2) was calculated by independent evaluator analysis employing digital photograph images and macroimage analysis software</description>
          <units>hairs/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.57" spread="60.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area</title>
        <description>Non-vellus terminal hair count was calculated across a tattooed 3 cm diameter scalp area from digital photographs of the area by independent blinded evaluator employing macroimage analysis software.</description>
        <time_frame>Baseline and 13 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erchonia MLS</title>
            <description>Erchonia MLS: The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area</title>
          <description>Non-vellus terminal hair count was calculated across a tattooed 3 cm diameter scalp area from digital photographs of the area by independent blinded evaluator employing macroimage analysis software.</description>
          <units>hairs/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>2 sided t-test for correlated samples.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erchonia MLS</title>
          <description>The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Consultant</name_or_title>
      <organization>Regulatory Insight, Inc.</organization>
      <phone>615-712-9743</phone>
      <email>elvira@reginsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

